TCR Vβ5, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-TCR Vβ5, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | TCR Vβ5, Human |
| Clone | REA910 |
| Host Species | Recombinant Human |
| Reactive Species | human, nonhuman primate |
| Isotype | IgG1 |
| Format | APC-Vio 770 conjugate |
| Size | 30 tests in 60 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | TCR Vβ5 Antibody, anti-human, APC-Vio® 770, REAfinity™. Clone REA910 recognizes the human variable β 5 subunit of the αβ T cell receptor (TCR Vβ5). The TCR is a heterodimeric glycoprotein associated with the CD3 antigen. The α and β TCR chains are composed of constant and variable regions, each encoded by distinct gene segments. TCR Vβ5 is a variant of the TCR β chain. αβ T cells express a diverse αβ TCR repertoire that specifically co-recognizes self or foreign antigen bound to antigen-presenting molecules, which thereby leads to T cell-mediated immunity. For example, the TCR can directly bind to peptide fragments, riboflavin precursors, and lipid antigens that are presented by major histocompatibility complex (MHC) molecules, MR1 and CD1, respectively. In each case, the antigen sits within the antigen-binding cleft, whereupon the TCR recognizes a composite surface formed by the antigen-presenting molecule and surface-exposed regions of the antigen itself. This co-recognition paradigm is a central tenet of αβ T cell-mediated immunity and underpins MHC restriction. | Additional information: Clone REA910 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | TCR Vb5, TCR Vbeta5 |
| Gene, Accession # | Gene ID: 28614, 28613 |
| Catalog # | 130-115-094 |
| Price | $158 |
| Order / More Info | TCR Vβ5, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Wei, S. et al. (1994) The extent of the human germline T-cell receptor V beta gene segment repertoire. Immunogenetics 40 (1): 27-36. | Killestein, J. et al. (2002) Antibody-mediated suppression of Vbeta5.2/5.3+ T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann. Neurol. 51 (4): 467-474. | Joedicke, J. J. et al. (2014) Activated CD8+ T cells induce expansion of Vβ5+ regulatory T cells via TNFR2 signaling. J Immunol 193 (6): 2952-2960. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG